No problem. And I don't think it's particularly relevant that this is "old info" from 6 months ago. Unless I'm mistaken, Remdesivir is still widely viewed as the standard of care simply because it was the best of a bad bunch of options for treating Covid, and therefore is the treatment that Brilicidin is being compared to in the current clinical trials. If this printed WHO view (that Remdesivir is NOT significantly helping hospitalized Covid patients) is becoming more widely accepted as true, then SOMEONE (maybe a physician involved in an active drug study, or possibly a "Big Pharma" executive "somewhere" might ASSUME by association that the "new" treatment drug might be responsible for any positive changes seen in all the patients. ASSUMPTIONS are quite often faulty, but given this scenario it seems like some relevant persons MIGHT jump to that conclusion before the study is "officially" completed. Might then those "relevant persons" start acting on their assumptions? Maybe start buying a little stock somewhere, or maybe telling their friends about it and suggesting buying, or maybe advising a company board that they should look at this closely? All just speculation on my part about what SOME PEOPLE might be starting to think SOMEWHERE. Not really related to anything, is it?